随机II期试验：不可避免还是不可取？ - Suppr

Suppr

超能文献

Randomized phase II trials: inevitable or inadvisable?

作者信息

Gan Hui K, Grothey Axel, Pond Gregory R, Moore Malcolm J, Siu Lillian L, Sargent Daniel

机构信息

Princess Margaret Hospital, Toronto, ON, Canada.

出版信息

J Clin Oncol. 2010 May 20;28(15):2641-7. doi: 10.1200/JCO.2009.26.3343. Epub 2010 Apr 20.

DOI:10.1200/JCO.2009.26.3343

PMID:20406933

Abstract

摘要

相似文献

Randomized phase II trials: inevitable or inadvisable?

J Clin Oncol. 2010 May 20;28(15):2641-7. doi: 10.1200/JCO.2009.26.3343. Epub 2010 Apr 20.

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.

Clin Cancer Res. 2007 Feb 1;13(3):781-2. doi: 10.1158/1078-0432.CCR-06-2533.

Optimal designs for two-arm, phase II clinical trial design with multiple constraints.

J Biopharm Stat. 2010 Jan;20(1):106-24. doi: 10.1080/10543400903280597.

Optimal two-stage randomized multinomial designs for Phase II oncology trials.

J Biopharm Stat. 2009;19(3):485-93. doi: 10.1080/10543400902802417.

Improving the design of phase II trials of cytostatic anticancer agents.

Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

How to ensure clinical trial sensitivity in psychotropic drug development: a case study.

Clin Ther. 2005 Feb;27(2):252-4. doi: 10.1016/j.clinthera.2005.02.005.

Optimizing randomized phase II trials assessing tumor progression.

Contemp Clin Trials. 2007 Feb;28(2):146-52. doi: 10.1016/j.cct.2006.05.003. Epub 2006 May 19.

Newer phase II trial designs gaining ground.

J Natl Cancer Inst. 2007 Oct 3;99(19):1428-9. doi: 10.1093/jnci/djm182. Epub 2007 Sep 25.

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.

Cancer J. 2009 Sep-Oct;15(5):426-30. doi: 10.1097/PPO.0b013e3181b9c5d5.

引用本文的文献

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Trials. 2023 Sep 15;24(1):591. doi: 10.1186/s13063-023-07421-x.

A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer.

Front Oncol. 2023 Jul 11;13:1048242. doi: 10.3389/fonc.2023.1048242. eCollection 2023.

The Trial within Cohorts (TwiCs) study design in oncology: experience and methodological reflections.

BMC Med Res Methodol. 2023 May 13;23(1):117. doi: 10.1186/s12874-023-01941-5.

Optimal predictive probability designs for randomized biomarker-guided oncology trials.

Front Oncol. 2022 Dec 6;12:955056. doi: 10.3389/fonc.2022.955056. eCollection 2022.

The design and evaluation of hybrid controlled trials that leverage external data and randomization.

Nat Commun. 2022 Oct 2;13(1):5783. doi: 10.1038/s41467-022-33192-1.

Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.

Cancer. 2022 Nov 1;128(21):3775-3783. doi: 10.1002/cncr.34445. Epub 2022 Sep 13.

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Ther Adv Med Oncol. 2021 Jul 31;13:17588359211036544. doi: 10.1177/17588359211036544. eCollection 2021.

The use of external control data for predictions and futility interim analyses in clinical trials.

Neuro Oncol. 2022 Feb 1;24(2):247-256. doi: 10.1093/neuonc/noab141.

Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.

BMC Med Res Methodol. 2020 May 20;20(1):126. doi: 10.1186/s12874-020-01017-8.

Phase II Trials in Drug Development and Adaptive Trial Design.

JACC Basic Transl Sci. 2019 Jun 24;4(3):428-437. doi: 10.1016/j.jacbts.2019.02.005. eCollection 2019 Jun.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验